FERNANDO TAVERAS: Open Payments
NPI 1194769067 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,880 in 191 payments from 15 companies in 2025. Trend: 2023 $2,509 · 2024 $2,694 · 2025 $4,880
Food & beverage: $4,786Education: $94
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 39 | $1,068 |
| Axsome Therapeutics, Inc. | 23 | $591 |
| ABBVIE INC. | 23 | $575 |
| E.R. Squibb & Sons, L.L.C. | 16 | $495 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $411 |
| Otsuka America Pharmaceutical, Inc. | 21 | $395 |
| Vanda Pharmaceuticals Inc. | 11 | $341 |
| Teva Pharmaceuticals USA, Inc. | 13 | $297 |
| Neurocrine BioSciences, Inc. | 13 | $268 |
| Lundbeck LLC | 13 | $204 |
Products named: Auvelity, VIVITROL, VRAYLAR, COBENFY, REXULTI, CAPLYTA, ARISTADA, INGREZZA.
Industry payments across NY — which companies pay providers there.
